Add BrightSurf on Google Email

Contribution of cannabis use disorder to new cases of schizophrenia has almost tripled over the past 17 years

A new study found that cannabis use disorder is increasingly associated with new schizophrenia cases in Ontario, with the proportion rising from 4% to 10%. The trend has tripled over the past 17 years, with heavy cannabis use linked to worsening symptoms and increased risk of psychosis.

SourceInstitute for Clinical Evaluative Sciences·JournalJAMA Network Open·TypeObservational study·DateFeb 4, 2025

Race and ethnicity and diffusion of telemedicine in Medicaid for schizophrenia care after onset of the COVID-19 pandemic

A cohort study of Medicaid beneficiaries with schizophrenia reveals rapid diffusion of telemedicine care following the COVID-19 pandemic. Within-agency racial and ethnic differences in telemental health care adoption were observed, underscoring the need for monitoring innovation diffusion across vulnerable populations.

SourceJAMA Network·JournalJAMA Network Open·DateJan 16, 2025

New study reveals immune system changes linked to schizophrenia and treatment resistance

Researchers found significant differences in immune cell populations between healthy individuals and people with schizophrenia, with the CD4/CD8 ratio emerging as a potential biomarker for predicting treatment response. Lower levels of mucosal-associated invariant T cells may signify immune dysregulation in schizophrenia.

SourceAgency for Science, Technology and Research (A*STAR), Singapore·JournalBrain Behavior and Immunity·TypeExperimental study·DateJan 15, 2025

Research reveals unique features of brain cells linked to neurodevelopmental conditions

A recent study has identified distinct features in two types of brain cells, intratelencephalic (IT) neurons and pyramidal tract (PT) neurons, which may affect their vulnerability to neurodevelopmental conditions. The research highlights the importance of understanding how these brain cells exchange information through their synapses.

SourceVlaams Instituut voor Biotechnologie·JournalNature Communications·TypeExperimental study·DateJan 7, 2025

UT Health San Antonio study links genetic changes to social behavior differences in autism, schizophrenia

A UT Health San Antonio study found that brain volume changes correlate with social behavior differences in psychiatric conditions such as autism spectrum disorder and schizophrenia. Tbx1 deficiency was associated with decreased brain volume in the amygdala and surrounding cortical regions, affecting desire for social interaction.

SourceUniversity of Texas Health Science Center at San Antonio·JournalMolecular Psychiatry·TypeExperimental study·DateDec 5, 2024

Scanning synaptic receptors: A game-changer for understanding psychiatric disorders

Researchers developed a method to visualize AMPA receptors using PET scans, revealing differences in density and distribution between healthy subjects and those with psychiatric disorders. This discovery may lead to new diagnostic and therapeutic approaches for conditions like schizophrenia, bipolar disorder, and autism spectrum disorder.

SourceYCU Advanced Medical Research Center·JournalMolecular Psychiatry·TypeObservational study·DateNov 5, 2024

New research identifies critical gaps in mental health care for adults with schizophrenia spectrum disorders

New research identifies critical gaps in mental health care for adults with schizophrenia spectrum disorders. Adults with schizophrenia spectrum disorders experience high rates of comorbid conditions, such as major depressive episode and post-traumatic stress disorder. The study found that only 26% received minimally adequate treatment.

SourceAmerican Psychiatric Association·JournalPsychiatric Services·TypeData/statistical analysis·DateSep 23, 2024

Groundbreaking study shows promise for early detection and intervention in psychotic disorders such as schizophrenia

Researchers have discovered a link between cognitive impairments and brain network organization in individuals at risk of developing psychotic disorders such as schizophrenia. This finding suggests an opportunity for early diagnosis and intervention, potentially through non-invasive neuromodulation.

SourceElsevier·JournalBiological Psychiatry·TypeImaging analysis·DateAug 20, 2024

Pink elephants in the brain?

A study published in Neuron reveals that neurons are wired to connect seemingly unrelated concepts, enhancing the brain's ability to predict what we see based on past experiences. Visual experience influences the organisation of feedback projections, which store information about the world.

SourceChampalimaud Centre for the Unknown·JournalNeuron·TypeExperimental study·DateAug 12, 2024

A new study reveals the underuse of a key drug in patients with treatment-resistant schizophrenia

A new study analyzed clozapine prescription patterns in patients with first-episode psychosis, finding that approximately 20-30% do not respond to conventional treatments. The use of clozapine can significantly reduce psychotic symptoms and improve quality of life for these patients.

SourceGermans Trias i Pujol Research Institute·JournalSpanish Journal of Psychiatry and Mental Health·TypeExperimental study·DateJul 11, 2024

Novel peptide formulation shows promise of restoring cognitive decline in schizophrenia

A novel peptide, KS-133, has been developed to target genetic mechanisms associated with schizophrenia. The nanoparticle-based drug delivery system, where KS-133 is encapsulated with a brain-targeting peptide, shows effective distribution in the brains of mice and improves cognitive functions in mice with induced schizophrenia.

Two new studies by Mount Sinai researchers in science offer key insights into the origins and potential treatment of mental health disorders

Two studies published in Science reveal significant advances in understanding the molecular biology of neuropsychiatric disease, including a comprehensive map of regulatory components of the brain. The research provides critical insights into the pathogenesis of mental health disorders and holds promise for therapeutic applications.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalScience·TypeData/statistical analysis·DateMay 23, 2024

Can probiotics plus vitamin D supplements benefit people with schizophrenia?

A randomized controlled trial found that co-administration of probiotic and vitamin D supplements improved MoCA scores and increased the percentage of patients with normal cognition in individuals with schizophrenia. The study suggests that probiotics may be a novel way to treat mental disorders by regulating gut microbiota.

SourceWiley·JournalNeuropsychopharmacology Reports·DateApr 10, 2024

From autism to Alzheimer’s: A large-scale animal study links brain pH changes to wide-ranging cognitive issues

A large-scale animal study reveals that brain pH and lactate levels are a common feature across various neuropsychiatric conditions, including schizophrenia, bipolar disorder, autism, depression, epilepsy, and Alzheimer's disease. Changes in brain energy metabolism are linked to cognitive impairment, particularly working memory.

SourceFujita Health University·JournaleLife·TypeData/statistical analysis·DateMar 26, 2024

Researchers uncover new clues about links between parent age and congenital disorders

A new study found that the link between paternal age and rare congenital disorders is more complex than previously thought. Researchers discovered that while older fathers are more likely to have children with certain bone and heart malformations, some genetic mutations associated with these conditions do not increase with paternal age.

SourceOxford University Press USA·JournalGenome Biology and Evolution·TypeContent analysis·DateFeb 27, 2024